Патология сердечно-сосудистой системы при ромегалии

1. Baldelli R, Ferretti E, Jaffrain-Rea ML, Iacobellis G, et al. Cardiac effects of lanreotide, a slow release somatostatin analog, in acromegalic patients. J. Clin. Endocrinol. Metab. 1999;84:575-532.

2. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenectomy for acromegaly. Clin. Endocrinol. 2003;58:86-89.

3. Bihan H, Espinosa C, Valdes-Socin H, Salenave S, Young J, Levasseur S, Assayag P, Beckers A, Chanson Ph. Long-Term Outcome of Patients with Acromegaly and Congestive Heart Failure. J Clin Endocrinol Metab 2004;89:5308-5313.

4. Chanson P, Timsit J, Masquet C, Warnet A, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990;113:921-925.

5. Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impared glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000;85:193-199.

6. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Perretta M, Salvatore M, Lombardi G. Impact of patient's age and disease duration on cardiac performance in acromegaly. A radionuclide angiography study. J. Clin. Endocrinol. Metab. 1999;84:1518-1523.

7. Colao A, Cuocolo A, Marzullo P, Nicolai E, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 2001;86:1551-1557.

8. Colao A, Cuocolo A, Marzullo P, Nicolai E, et al. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab. 1999;84:17-23.

9. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly epidemiology, pathogenesis and management. Endocr. Rev. 2004;25:102-152.

10. Colao A, Marzullo P, Cuocolo A, Spinelli L, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin. Endocrinol. 2003;58:169-176.

11. Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin. Endocrinol. 2001;54:137-154.

12. Colao A, Marzullo P, Ferone D, Spinelli L, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LARw in acromegaly. J. Clin. Endocrinol. Metab. 2000;86:3132-3140.

13. Colao A, Merola B, Ferone D, Lombardi G. Extensive personal experience:acromegaly. J. Clin. Endocrinol. Metab. 1997;82:2777-2781.

14. Colao A, Spinelli L, Cuocolo A, Spiezia S, et al. Cardiovascular consequences of early-onset growth hormone excess. J. Clin. Endocrinol. Metab. 2002;87:3097-3104.

15. Colao A, Spinelli L, Marzullo P, Pivonello R, et al. High prevalence of cardiac valve disease in acromegaly:an observational, analytical, casecontrol study. J. Clin. Endocrinol. Metab. 2003;88:3196-3201.

16. Colao A. Are patients with acromegaly at risk for dysrhythmias? Clin. Endocrinol. 2001;55:305-306.

17. Fazio S, Cittadini A, Biondi B, Palmieri EA, et al. Cardiovascular effects of short-term growth hormone hypersecretion. J. Clin. Endocrinol. 2000;85:179-182.

18. Fazio S, Cittadini A, Sabatini D, et al. Evidence for biventricular invovment in acromegaly: a Doppler echocardiographic study. Eur. Heart J. 1993;14:26-33.

19. Ferone D, Colao A, van der Lely AJ, Lamberts SW. Pharmacology and surgery as primary therapy fpr acromegaly? Drugs Aging. 2000;17:81-92.

20. Frustaci A, Chimenti C, Setoguchi M, Guerra S, et al. Cell death in acromegalic cardiomyopathy. Circulation. 1999;99:1426-1434.

21. Hayward RP, Emanuel RW, Nabarro JDN. Acromegalic heart disease:influence of treatment of the acromegaly on the heart. Quart. J. Med. 1987;62:41-45.

22. Herrington AM, George KW, Moulds CC. Octreotide-induced bradycardia. Pharmacotherapy. 1998;18:413-416.

23. Herrmann BL, Bruch C, Saller B, Ferdin S, et al. Occurrence of left ventricular late potentials in patients active acromegaly. Clin. Endocrinol. 2001;55:201-207.

24. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab.2004;89:667-674.

25. Hradec J, Kral J, Janota T, Krsek M, et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am.J. Cardiol. 1999;83:1506-1509.

26. Huchard H. Anatomic pathologique, lesions et troubles cardiovasculaires de l'acromegalie. J. Praticiens. 1895;9:249- 251.

27. Kahaly G, Stover C, Beyer J, Mohr-Kahaly S. Relation of endocrine and cardiac findings in acromegalics. J. Endocrinol. Invest. 1992;15:13-18.

28. Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N. Engl. J. Med. 1996;334:246-254.

29. Legrand V, Beckers A, Pham VT, Demoulin JC, et al. Dramatic improvement of severe dilated cardiomyopathy in an acromegalic patient after treatment with octreotide and trans-sphenoidal surgery. Eur. Heart. J 1994;15:1286-1289.

30. Lie JT, Grossman SJ. Pathology of the heart in acromegaly anatomic findings in 27 autopsied patients. Am. Heart J. 1980;100:41-44.

31. Lombardi G, Colao A, Cuocolo A et al. Cardiological aspects of growth hormone and insulin-like factor-1. J. Pediatr. Endocrinol. Metab. 1997;10:553-560.

32. Lombardi G, Colao A, Marzullo P, Biondi B, et al. Multicenter Italian Study Group on Lanreotide. Improvement of left ventricular hypertrophy and arrhythmias after lanreotideinduced GH and IGF-I decrease in acromegaly. A prospective multicenter study. J. Endocrinol. Invest. 2002;25:971-976.

33. Lopez-Velasco R, Escobar-Morreale HF, Vega B, et al. Cardiac involvement in acromegaly:specific cardiomyopathy or consequence of systemic hypertension? J. Clin. Endocrinol. Metab. 1997;82:1047-1053.

34. Manelli F, Desenzani P, Boni E, Bugari G, et al. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary. 1999;2:205-210.

35. McGuffin WL Jr, Sherman BM, Roth J, Gorden P, et al. Acromegaly and cardiovascular disorders:a prospective study. An. Int. Med. 1974;81:11-18.

36. Merola B, Cittadini A, Colao A, Ferone D, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J. Clin. Endocrinol. Metab. 1993;77:790-793.

37. Minniti G, Jaffrain-Rea MI, Moroni C, et al. Echocardiographic evidence for a direct effect of GH/IGF-1 hypersecretion on cardiac mass and function in young acromegalics. Clin. Endocrinol. 1998;49:101-106.

38. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, et al. Increased prevalence of regurgitation valvular heart disease in acromegaly. J. Clin. Endocrinol. Metab. 2004;89:71-75.

39. Pereira J, Rodriguez-Puras MJ, Leal-Cerro A, Martinez A, et al. Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. J. Endocrinol. Invest. 1991;14:17-23.

40. Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr. Rev. 1994;15:555- 573.

41. Sacca L, Napoli R, Cittadini A Growth hormone, acromegaly, and heart failure:an intricate triangulation. Clin. Endocrinol. (Oxf) 2003;59:660-671.

42. Surawicz B, Mangiardi ML. Electrocardiogram in endocrine and metabolic disorders. Cardiovasc. Clinics. 1977 8 243-247.

43. Swearingen B, Barker FG II, Katznelson L, Biller BM, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegly. J. Clin. Endocrinol. Metab. 1998;83:3419-3426.

44. Timsit J, Riou B, Bertherat J Wisnewsky C, et al. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pettern, and myosin adenosinetriphophatase activity of rat left vantricle. J Clin. Invest. 1990;86:507-515.

45. Tokgoђzoglu SL, Erbas T, Aytemir K, Akalin S, et al. Effects of octreotide on left ventricular mass in acromegaly. Am. J. Cardiol. 1994;74:1072-1074.

46. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Quart. J. Med. 1971;39:1-16.